CRESCENT BIOPHARMA, INC. Net Income Loss

Quick Answer

CRESCENT BIOPHARMA, INC. reported Net Income Loss of -$153.94 million for the year ending 2025.

  • CRESCENT BIOPHARMA, INC. showed a decrease of -306.4% in Net Income Loss from 2024 to 2025.
  • This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 14 years of available data (2012 to 2025), CRESCENT BIOPHARMA, INC.'s Net Income Loss has declined by 4,310.6%.
  • Historical annual values: Fiscal year 2025: -$153.94 million | Fiscal year 2024: -$37.88 million | Fiscal year 2023: -$36.90 million | Fiscal year 2022: -$46.69 million | Fiscal year 2021: -$63.43 million | Fiscal year 2020: -$51.03 million | Fiscal year 2019: -$57.89 million | Fiscal year 2018: -$48.27 million | Fiscal year 2017: -$33.28 million | Fiscal year 2016: -$31.81 million | Fiscal year 2015: -$12.77 million | Fiscal year 2014: -$11.12 million | Fiscal year 2013: -$10.61 million | Fiscal year 2012: $3.66 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: